ArticleThe Kaohsiung journal of medical sciences2026
Andrographolide Modulates Fibrogenic and Oxidative Stress Responses in Human Lung Fibroblasts.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pulmonary fibrosis is a progressive lung disorder characterized by fibroblast activation and excessive extracellular matrix deposition. Andrographolide (ANDRO) has been reported to attenuate pulmonary fibrosis, but the underlying molecular mechanisms remain incompletely understood. In this study, we investigated the effects of ANDRO on transforming growth factor-beta 1 (TGF-β1)-induced fibrogenesis in human lung fibroblasts. Comprehensive transcriptomic analysis revealed that ANDRO reversed TGF-β1-perturbed genes associated with fibrogenesis and glutathione (GSH) metabolism. Functionally, ANDRO restored TGF-β1-inhibited total GSH levels and suppressed TGF-β1-induced reactive oxygen species (ROS) accumulation. Together, these findings identify GSH metabolism as a previously unrecognized mechanism underlying the antifibrotic effects of ANDRO in human lung fibroblasts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.